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The placenta is a hematopoietic organ that supports
hematopoietic stem/progenitor cell (HSPC) genera-
tion and expansion without promoting differentia-
tion. We identified PDGF-B signaling in trophoblasts
as a key component of the unique placental hemato-
poietic microenvironment that protects HSPCs from
premature differentiation. Loss of PDGF-B or its
receptor, PDGFRb, induced definitive erythropoiesis
in placental labyrinth vasculature. This was evi-
denced by accumulation of CFU-Es and actively
proliferating definitive erythroblasts that clustered
around central macrophages, highly reminiscent of
erythropoiesis in the fetal liver. Ectopic erythropoi-
esis was not due to a requirement of PDGF-B sig-
naling in hematopoietic cells but rather in placental
trophoblasts, which upregulated Epo in the absence
of PDGF-B signaling. Furthermore, overexpression
of hEPO specifically in the trophoblasts in vivo was
sufficient to convert the placenta into an erythro-
poietic organ. These data provide genetic evidence
of a signaling pathway that is required to restrict ery-
throid differentiation to specific anatomical niches
during development.
INTRODUCTION
The goals of developmental hematopoiesis are to generate
differentiated blood cells for the fetus while establishing a pool
of undifferentiated hematopoietic stem cells (HSCs) for postnatal
life. This is achieved by segregating fetal hematopoiesis into
multiple waves and different microenvironmental niches that
protect undifferentiated hematopoietic stem/progenitor cells
(HSPCs) or promote differentiation (Mikkola and Orkin, 2006).
The first wave of hematopoiesis begins in the yolk sac with the
formation of primitive erythroblasts that fulfill the immediate
oxygen needs of the embryo, and macrophages that assist inDevelotissue remodeling (Palis et al., 2001). In the second wave, the
yolk sac generates a transient pool of definitive progenitors
that seed the fetal liver to launch definitive erythropoiesis and
myelopoiesis. Finally, in the third wave, the multipotent, self-
renewing HSCs develop in the major arteries in the AGM
(aorta-gonad mesonephros) region, the placenta, and the yolk
sac, after which they expand in the placenta and the fetal liver
before colonizing the bone marrow (Chen et al., 2009; Mikkola
andOrkin, 2006; Rhodes et al., 2008; Zovein et al., 2008). Several
niche cells, such as endothelial, endosteal, and mesenchymal
cells, and macrophages regulate HSCs in the bone marrow
(Chow et al., 2011; Kiel and Morrison, 2008). However, the
cellular and molecular mechanisms promoting stemness versus
differentiation in fetal hematopoietic niches remain undefined.
The function of the placenta as a hematopoietic site was re-
cognized only recently (Alvarez-Silva et al., 2003). The placenta
is a unique hematopoietic organ that can generate multipotent
HSPCs de novo and support their expansion without promoting
differentiation (Gekas et al., 2005; Ottersbach and Dzierzak,
2005; Rhodes et al., 2008; Zeigler et al., 2006). HSPCs are gener-
ated in the large vessels in the chorioallantoic mesenchyme,
whereas the placental vascular labyrinth provides a niche where
HSPCs expand (Rhodes et al., 2008). The human placenta is also
populated by HSPCs throughout most of gestation (Ba´rcena
et al., 2009; Robin et al., 2009; Serikov et al., 2009). However,
the niche cells and signals that compose the unique placental
hematopoietic microenvironment are unknown.
The structure of the placental vascular labyrinth is compro-
mised in mouse embryos that lack PDGF-B signaling (Ohlsson
et al., 1999). PDGF-B signals through receptor tyrosine kinases
PDGF receptor (PDGFR)b and PDGFRa, influencing cell differen-
tiation, proliferation, migration, and survival in various organs
(Tallquist and Kazlauskas, 2004). Pdgf-b/ and Pdgfrb/
embryos die perinatally with strikingly similar phenotypes
(Leve´en et al., 1994; Soriano, 1994). In the placenta, PDGF-B
is expressed in the endothelium, some hematopoietic cells, and
trophoblasts, whereas PDGFRb is expressed in pericytes and
trophoblasts (Andrae et al., 2008; Holmgren et al., 1992). Loss
of the ligand or the receptor leads to a decrease in placental
trophoblasts and pericytes, and dilation of vasculature after mid-
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liver, as well as kidney and heart defects (Leve´en et al., 1994;
Soriano, 1994).
Here, we demonstrate that loss of PDGF-B signaling alters
the placental hematopoietic niche by upregulating Epo (Erythro-
poietin) levels in placental trophoblasts, which triggers ectopic
erythropoiesis in placental vasculature. These data establish
trophoblasts as important niche cells and PDGF-B signaling as
a critical molecular cue that prevent premature differentiation
of HSPCs in the placenta.
RESULTS
Pdgf-b–/– Embryos Display Ectopic Erythropoiesis
in Placental Labyrinth during Midgestation
To identify the cellular and molecular components of the
placental hematopoietic microenvironment, we asked whether
the compromise of the labyrinth structure in placentas that
lack PDGF-B signaling affects hematopoiesis. Consistent with
previous reports, the placentas in Pdgf-b/ embryos exhibited
dilation of labyrinth blood vessels and a reduction in trophoblasts
by E13.5 (Figure 1A). Interestingly, H&E revealed the presence of
clusters of blast-like cells with high nucleus to cytoplasmic ratio
within the Pdgf-b/ labyrinth vasculature (Figure 1B). These
blast clusters were first identified at E13.5, and by E18.5 they
contained cells that resembled maturing erythroblasts.
To define the identity of the blast cells in Pdgf-b/ placental
vasculature, immunohistochemistry (IHC) and immunofluores-
cence (IF) were performed. The blast cells did not express embry-
onic b-H1 globin, arguing against them being primitive erythroid
cells (Figure 1C). Most of the blast cells expressed the HSPC
marker c-Kit and erythroid marker Ter119, suggesting that they
were definitive erythroid precursors (Figure 1C). Ki67 staining
indicated that the blast cells were actively cycling (Figure 1D).
Methylcellulose colony assay confirmed a drastic increase in
erythroid-committedprogenitors,CFU-Es, inPdgf-b/placentas
(Figure1E). These results suggested that theplacenta inPdgf-b/
embryos had started to support definitive erythropoiesis,
a process that should be restricted to the fetal liver at this stage.
We next investigated whether the blast cells in the placenta
differentiated into other hematopoietic lineages. Some blast
cells expressed CD41, a marker of nascent HSPCs and
megakaryocytes/platelets (see Figure S1A available online), but
not GP1b-b, which implied that they were not megakaryocytes.
The blast cells neither expressed HSC markers Sca1 or CD150,
nor the B-lymphoid marker B220; however, some expressed
the pan-hematopoietic marker CD45. Strong CD45 expression
(Figure S1A) was also observed in large cells that were identified
as macrophages based on expression of F4/80, but not other
myeloid markers (Mac1, Gr1, or FcRg) (Figure S1A). These
macrophages clustered togetherwith the blast cells in the vascu-
lature of Pdgf-b/ placentas (Figure 1F) in structures that were
highly reminiscent of the erythroblast-macrophage islands that
are characteristic of tissues supporting erythroid differentiation.
Ectopic Erythropoiesis in the Absence of PDGF-B
Signaling Is Specific to the Placenta
FACS analysis for erythroid maturation markers (Zhang et al.,
2003) confirmed a significant increase in proerythroblasts in652 Developmental Cell 22, 651–659, March 13, 2012 ª2012 Elsevierplacentas and circulating blood of Pdgf-b/ embryos (Fig-
ure S2A). Morphological analysis of hematopoietic cells in the
placenta and blood in Pdgf-b/ embryos verified the presence
of proerythroblasts and basophilic erythroblasts (Figure 2A),
whereas electron microscopy of the erythroblasts in Pdgf-b/
placentas confirmed the characteristic heterochromatin pattern
as observed in fetal liver erythroblasts (Figure 2B). Thus, the
ectopic erythropoiesis in Pdgf-b/ placentas had all the hall-
marks of definitive erythropoiesis.
Because the increase in erythroblasts was also noted in circu-
lating blood, a 1 hr BrdU incorporation assay was performed to
determine if the ectopic erythropoiesis was unique to the
placenta. FACS analysis revealed that only the placenta, and
not blood, fetal liver, yolk sac, or spleen, in Pdgf-b/ embryos
showed an increase in BrdU+CD71+ erythroblasts (Figure 2C
and data not shown). IF also evidenced prominent clusters of
BrdU+ cells in the vasculature ofPdgf-b/placentas (Figure 2C).
Thus, in the absence of PDGF-B, the placental labyrinth vascu-
lature specifically becomes a permissive environment for the
proliferation and differentiation of definitive erythroid precursors.
Erythropoiesis in Pdgf-b–/– Placentas Is Not Due
to an Intrinsic Requirement for PDGF-B Signaling
in Hematopoietic Cells
To determine if the ectopic definitive erythropoiesis observed in
Pdgf-b/ placentas could be due to a direct requirement of
PDGF-B signaling in hematopoietic cells, we examined the
expression of the receptor, PDGFRb, by FACS. Although no
surface expression of PDGFRbwas detected in circulating prim-
itive or fetal liver definitive erythroid cells (Figure S3A), PDGFRb
was expressed on a subset of c-Kit+ HSPCs in both the fetal liver
and the placenta (Figure S3B).
Thus, we utilized conditionally targeted Tie2Cre Pdgfrbfl/fl
embryos to delete PDGFRb in hematopoietic cells. FACS anal-
ysis at E14.5 revealed a complete loss of PDGFRb protein on
c-Kit+ HSPCs, as in Pdgfrb/ embryos (Figure S3C). However,
in contrast to Pdgfrb/ embryos that showed anemia in late
gestation, no obvious hematological abnormalities were ob-
served in Tie2Cre Pdgfrbfl/fl embryos (Table S1). Furthermore,
Ki-67 and BrdU staining evidenced clusters of proliferating blast
cells in Pdgfrb/ but not Tie2Cre Pdgfrbfl/fl placentas (Figures
3A and 3B). Ectopic definitive erythropoiesis in Pdgfrb/
placentas was further confirmed by FACS analysis (accumula-
tion of CD71+Ter119+ erythroblasts, Figure S3D) and CFU-E
assay (Figure 3C), whereas Tie2Cre Pdgfrbfl/fl placentas showed
no signs of erythropoiesis. Similar data were obtained when both
PDGFRs, Pdgfrb and Pdgfra, were deleted in hematopoietic cells
(data not shown). These data imply that the ectopic definitive
erythropoiesis in Pdgf-b/ and Pdgfrb/ placentas is not due
to a requirement of PDGFRb signaling in hematopoietic cells.
Ectopic Definitive Erythropoiesis in PDGF-B-Deficient
Placentas Occurs prior to Other Hematological Defects
Because Pdgf-b/ embryos display abnormalities in multiple
organs, we investigated whether hemorrhaging, anemia, and
other organ defects could underlie the ectopic erythropoiesis in
the placenta. Consistent with previous studies, Pdgf-b/
embryos displayed bleeding and edema perinatally (E18.5);
however, these abnormalities were not observed at E13.5–E15.5Inc.
Figure 1. Pdgf-b–/– Embryos Support Ectopic Erythropoiesis in Placental Labyrinth Vasculature during Midgestation
(A) IHC for CD31 (endothelium) and cytokeratin (trophoblasts) documents progressive dilation of the labyrinth vasculature (arrows) in Pdgf-b/ placentas at
E13.5–E18.5. Scale bar, 100 mm.
(B) H&E reveals clusters of blast-like cells in Pdgf-b/ placental vasculature at E13.5–E18.5 (arrows, insets). Scale bar, 100 mm.
(C) IHC shows that majority of the blast cells (arrow, inset) in Pdgf-b/ placentas do not express b-H1 globin (primitive RBCs, arrowhead), but express c-Kit
(HSPCs). Dlk marks placental vasculature. IF shows coexpression of c-Kit and Ter119 (erythroid cells) in the blasts (arrow). Scale bars, 50 mm.
(D) IHC for Ki-67 (proliferation) and cytokeratin implies that the blast cells (arrow, inset) in Pdgf-b/ placentas are actively cycling. Scale bar, 50 mm.
(E) Bright-field image of CFU-Es. Increase in CFU-Es is observed in Pdgf-b/ placentas compared to controls. Error bars represent SEM (n = 6 for each
genotype; **p < 0.005).
(F) IF for F4/80 identifies macrophages within the blast cell clusters (DAPI) in Pdgf-b/ placental vasculature (CD31) (arrow). Scale bar, 50 mm.
See also Figure S1.
Developmental Cell
PDGF-B Regulates the Placental Hematopoietic Nichewhen ectopic erythropoiesis was already evident (Figure S4A)
(Leve´en et al., 1994). By E16.5 and E18.5 both Pdgf-b/ and
Pdgfrb/ embryos showed anemia (Table S1); however, the first
sign of reduced blood cell counts was observed only after E13.5,
when the erythroblast clusters were already evident in theDeveloplacenta (Figures S4B and 1B). Furthermore, reduction in fetal
liver size inPdgf-b/embryoswasobservedonly in lategestation
(Figure S4C). These data indicate that the ectopic definitive
erythropoiesis in Pdgf-b/ placentas precedes other macro-
scopic defects and anemia.pmental Cell 22, 651–659, March 13, 2012 ª2012 Elsevier Inc. 653
Figure 2. Loss of PDGF-B Promotes Proliferation of Erythroid Precursors Specifically in the Placenta
(A) MGG staining shows proerythroblasts and basophilic erythroblasts (arrows) in Pdgf-b/ placenta and blood.
(B) Electron microscopy (magnification 2,9003) documents similar morphology of the erythroblasts (arrow) in Pdgf-b/ placentas as in normal fetal liver (arrow).
(C) FACS after 1 hr BrdU incorporation shows increase in BrdU+CD71+ erythroblasts only in placentas of E14.5 Pdgf-b/ embryos. Representative examples
from three experiments are shown; error bars represent SEM (n = 6 for each genotype). IF for BrdU, CD31 (endothelium), and DAPI (nuclei) verifies proliferation of
the blast cells in placental vasculature (arrow, inset). Scale bar, 50 mm.
See also Figure S2.
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PDGF-B Signaling by Hypoxia-Independent Mechanism
Because the ectopic erythropoiesis in Pdgf-b/ and Pdgfrb/
placentas was neither explained by lack of signaling in hemato-
poietic cells nor anemia, we hypothesized that this phenotype
may be due to the absence of PDGF-B signaling in the cells of
the microenvironment, many of which express the receptor (Fig-
ure 4B) (Andrae et al., 2008; Holmgren et al., 1991, 1992).
Because previous reports had documented increased Epo levels
in Pdgf-b/ embryos (Kaminski et al., 2001), we asked whether
Epo was upregulated in Pdgf-b/ placentas. Interestingly, a
profound increase in Epo expression was noted specifically in
placental trophoblasts in both Pdgf-b/ (Figure 4A) (8.22- ±
6.64-fold increase at E15.5) and Pdgfrb/ embryos (3.32- ±
1.19-fold increase).654 Developmental Cell 22, 651–659, March 13, 2012 ª2012 ElsevierBecause Epo expression can be upregulated in the placenta
during hypoxia (Trollmann et al., 2008), we asked if the structural
defects in Pdgf-b/ placentas could lead to insufficient fetal-
maternal exchange and increased hypoxia. However, no sig-
nificant increase in pimonidazole incorporation (Figure S4D) or
mRNA transcripts for known hypoxia indicators (Glut1, Ldh-A,
and Pgk) (Figure S4E) was observed, suggesting that lack of
PDGF-B signaling does not lead to severe hypoxia in the
placenta.
PDGF-B Signaling Is Required in Trophoblasts
to Suppress Epo Secretion
To investigate if Epo upregulation in the placenta could be
caused by a direct requirement of PDGF-B signaling in tropho-
blasts, we localized the expression of PDGFRb and Epo. BothInc.
Figure 3. Erythropoiesis in Pdgf-b–/– Placentas Is Not due to Intrinsic Requirement for PDGF-B Signaling in Hematopoietic Cells
(A) H&E shows the presence of clusters of blast cells (arrow, inset) in E14.5 Pdgfrb/ placentas, but not in Tie2Cre Pdgfrbfl/fl placentas. IHC for Ki-67 indicates
active proliferation of blast cells (arrow, inset) in Pdgfrb/ placental vasculature (Dlk). Scale bar, 100 mm.
(B) FACS analysis shows an increase in BrdU+CD71+ erythroblasts in Pdgfrb/ placentas, but not in Tie2Cre Pdgfrbfl/fl placentas. Representative examples from
three experiments are shown; error bars represent SEM (n = 5 for each genotype; **p < 0.005). IF for BrdU, DAPI (nuclei), and CD31 (endothelium) verifies the
presence of clusters of proliferative blast cells in placental vasculature in Pdgfrb/ (arrow, inset) but not Tie2Cre Pdgfrbfl/fl embryos. Scale bar, 50 mm.
(C) Significant increase in CFU-Es is seen in Pdgfrb/ but not Tie2Cre Pdgfrbfl/fl placentas (n = 3 for each genotype). Error bars represent SEM (**p < 0.005).
See also Figure S3.
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trophoblast giant cells (S-TGCs), which can be distinguished
by their location and large nucleus (Figures 4A and 4B) (Simmons
et al., 2007). In comparison, the main source of the ligand,DeveloPDGF-B, in the placenta during mid-late gestation is the endo-
thelium (Figure 4B). This suggested that PDGF-B signaling
between endothelium and trophoblasts directly regulates Epo
levels in the placenta.pmental Cell 22, 651–659, March 13, 2012 ª2012 Elsevier Inc. 655
Figure 4. Loss of PDGF-B Signaling in Trophoblasts Induces Epo Overexpression, which Promotes Ectopic Erythropoiesis
(A) IF for Epo, cytokeratin (trophoblasts), and DAPI (nuclei) (insets) documents upregulation of Epo in S-TGCs (arrows) in Pdgf-b/ placentas. Scale bar, 50 mm.
(B) IF for PDGFRb, PDGF-B, cytokeratin, CD34 (endothelium), and DAPI (insets) in E15.5 wild-type (WT) placentas reveals PDGFRb expression in S-TGCs
(arrows), whereas PDGF-B is expressed in the endothelium (asterisks). Scale bar, 50 mm.
(C) RT-PCR verifies knockdown of PDGFRb in BeWo trophoblast cells. Error bars represent SEM. Representative example from three experiments is shown (n = 9
for each vector; **p < 0.005).
(D) ELISA for hEPO documents significant increase in hEPO secretion per cell in shPDGFRb BeWo cells after 48 hr in culture. Error bars represent SEM.
Representative example from two experiments is shown (n = 6 for each vector; **p < 0.005).
(E) H&E for placentas overexpressing hEPO in the trophoblasts (EPO OE) shows clusters of blast cells (green arrows, insets). IHC shows the absence of b-H1
globin (primitive RBCs, arrowheads), but presence of Ter119 (yellow arrows, insets) expression in the blast cells (arrows, insets). IHC for Ki67 indicates prolif-
eration of the blasts (red arrows, insets) in placental vasculature (Dlk). F4/80 identifies macrophages (asterisks, insets) in the blast cell clusters. Scale bar, 100 mm.
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blasts regulates Epo expression, lentiviral shRNA was used to
knockdownPdgfrb in humanBeWo trophoblast cells (Figure 4C).
Transduced cells were cultured with PDGF-B for 48 hr, after
which secreted human EPO (hEPO) levels were measured by
ELISA. Strikingly, BeWo cells transduced with shPDGFRb
showed a significant increase in hEPO secretion (Figure 4D) as
compared to empty vector, implying a direct function of PDGF-B
signaling in regulating EPO secretion in trophoblasts.
Overexpression of EPO in Placental Trophoblasts Is
Sufficient to Induce Ectopic Erythropoiesis in Labyrinth
Vasculature
To investigate whether upregulation of Epo in placental tropho-
blasts was sufficient to induce erythropoiesis in the placenta,
we utilized a lentiviral gene transfer strategy that targets pla-
cental trophoblasts (Okada et al., 2007). Blastocysts were in-
jected with a lentiviral vector overexpressing hEPO; injection
under zona space results in integration of the vector into tropho-
blasts, whereas the extraembryonic mesoderm and the embryo
remain unaffected (Figures S4F and S4G). Similar to Pdgf-b/
and Pdgfrb/ placentas, placentas overexpressing hEPO dis-
played clusters of Ki-67+ definitive erythroblasts and macro-
phages in placental vasculature (Figure 4E). FACS analysis
also confirmed accumulation of CD71+Ter119+ erythroblasts in
placentas overexpressing hEPO and the blood of these embryos
(Figure S4H). These results suggest that increased Epo expres-
sion in the trophoblasts is responsible for induction of ectopic
definitive erythropoiesis in placental vasculature. These data
highlight the requirement for tight control of Epo levels in
placental trophoblasts (Figure 4F), and nominate PDGF-B sig-
naling as a key mechanism for maintaining the unique placental
hematopoietic microenvironment by regulating Epo levels.
DISCUSSION
Understanding the mechanisms by which the different fetal
hematopoietic niches support the development of undifferenti-
ated HSPCs versus promote lineage differentiation is a major
goal for the field. We document that loss of PDGF-B or its
receptor, PDGFRb, induces premature differentiation of hemato-
poietic progenitors into definitive erythroid cells in the placenta.
Ectopic erythropoiesis was caused by upregulation of Epo in
placental trophoblasts due to a direct requirement of PDGF-B
signaling in regulating Epo levels. These studies identify the
trophoblasts and PDGF-B signaling as key components of the
unique placental hematopoietic niche.
Trophoblasts are tropho-ectoderm derived epithelial-like cells
that facilitate implantation and maternal blood flow, and secrete
growth factors and hormones (Simmons and Cross, 2005). We
show that loss of PDGF-B signaling provokes upregulation of
Epo in S-TGCs, which secrete factors in fetal circulation (Sim-
mons et al., 2007).We discovered that S-TGCs express PDGFRb(F) Model for function of PDGF-B signaling in regulating Epo secretion from placen
on trophoblasts (brown) andmaintains Epo at basal levels. In the absence of PDGF
hematopoietic niche and induces ectopic definitive erythropoiesis (dark purple/l
PDGF-B signaling.
See also Figure S4.
Develo(receptor), but not PDGF-B (ligand), which is mainly expressed in
the endothelium during mid/late gestation, suggesting paracrine
signaling between endothelium and trophoblasts. Moreover,
mouse embryos that lack PDGF-B in the endothelium evi-
dence similar placental structural defects as in Pdgf-b/ and
Pdgfrb/ embryos, including reduction in trophoblasts, further
indicating that the endothelium is a critical source of PDGF-B
in the placenta (Bjarnega˚rd et al., 2004). Trophoblasts also ex-
press other growth factors and hormones that support hemato-
poiesis, such as VEGF, PLP-E, and PLP-F (Breier et al., 1995;
Lin et al., 1997; Simmons et al., 2008). However, unlike Epo,
these factors are not expressed in labyrinth S-TGCs (Lin et al.,
1997; Simmons et al., 2008; data not shown), implying a different
cellular origin and regulation. Future studies will be needed to
elucidate how the different trophoblast subtypes contribute to
the placental hematopoietic microenvironment.
Our study revealed that the ectopic erythropoiesis in placentas
lacking PDGF-B signaling was induced by upregulation of Epo in
trophoblasts. Epopromotes erythropoiesis by regulating prolifer-
ation and differentiation of erythroid progenitors (Wu et al., 1995).
Although Epo levels can be drastically upregulated during
anemia and hypoxia (Ebert and Bunn, 1999), we excluded these
conditions as amajor cause of Epo upregulation in PDGF-B defi-
cient embryos. Furthermore, although coexistence of placental
defects, hypocellular liver, and anemia has been described also
in other knockout mouse models such as p38a MAPK, SOCS3,
or c-Met (Adams et al., 2000; Marine et al., 1999; Roberts et al.,
2001; Sasaki et al., 2000; Tamura et al., 2000), Epo upregulation
and ectopic definitive erythropoiesis in the placenta have been
described so far only in embryos deficient for PDGF-B signaling.
The role of Epo in normal placental biology is largely unknown.
Epo signaling also acts in endothelial cells, supporting their
survival, proliferation, and migration (Anagnostou et al., 1990;
Carlini et al., 1995), and it has been suggested that Epo signaling
can regulate PDGF-B expression in the endothelium (Janmaat
et al., 2010). EpoR, the receptor for Epo, is expressed both in
placental vasculature and trophoblasts (Fairchild Benyo and
Conrad, 1999; Sawyer et al., 1989), suggesting that Epo may
also have an autocrine function in trophoblasts. Although the
physiological role of Epo signaling in the different placental cell
types is still largely undefined, the embryos lacking Epo signaling
possess smaller placentas (H. Wu, personal communication).
Our data also indicate that the placental Epo levels have to
be tightly regulated because the overexpression of Epo in the
trophoblasts is sufficient to induce ectopic definitive erythropoi-
esis in the placenta.
There aremajor differences in the regulation of Epo in the fetus
and adult. Although Epo production in the adult is restricted to
the kidney, during development the sites of Epo production
change temporally. Epo is first expressed in the yolk sac and
the placenta (Conrad et al., 1996; Ebert and Bunn, 1999; Yasuda
et al., 2002), after which its expression transitions to the fetal liver
(Lee et al., 2001) and at around birth to the kidney (Dame et al.,tal trophoblasts. PDGF-B from the endothelium (bright pink) activates PDGFRb
-B signaling, placental trophoblasts upregulate Epo, which alters the placental
ight pink) in association with macrophages (light blue). X indicates absence of
pmental Cell 22, 651–659, March 13, 2012 ª2012 Elsevier Inc. 657
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pose a risk for ectopic erythropoiesis because HSPCs reside in
their niche in the bone marrow, whereas during fetal life, HSPCs
traffic between the different hematopoietic niches, exposing
HSPCs to signals they encounter during migration. Furthermore,
it has been suggested that fetal progenitors aremore sensitive to
Epo than their adult counterparts (Linch et al., 1982). Hence, the
niche-restricted Epo production may be essential to facilitate
HSPCmigration between the fetal hematopoietic organs without
exposing them to premature differentiation.
The discovery of PDGF-B signaling in the trophoblasts as an
important regulator of local Epo levels in the placenta reveals
a developmental stage and niche-specific mechanism for regu-
lating Epo expression, which is critical for governing the fate of
HSPCs during their developmental journey. This work gives
insights into the goal of recreating the different types of hemato-
poietic niches in vitro, aswell as furthers our understanding of the
etiology of developmental defects originating from the placenta.
EXPERIMENTAL PROCEDURES
Documentation of Ectopic Erythropoiesis in the Placenta
All animal experiments were performed in accordance with the guidelines of
the Chancellor’s Animal Research Committee at UCLA. Placenta and other
hematopoietic tissues from Pdgf-b/, Pdgfrb/, Tie2Cre Pdgfrbfl/fl, and
control embryos were analyzed for evidence of proliferation and differentiation
of erythroid cells. See Supplemental Experimental Procedures for details for
IHC, IF, and FACS. Erythroid progenitors in placentas were quantified by
CFU-E assay (Methocult M3334; Stem Cell Technologies) 3–4 days after
plating. Colonies were imaged using a Canon PowerShot G6 camera con-
nected to a Zeiss Axiovert 40 CFL microscope via a 52 mm Hama adaptor.
Complete blood count (CBC) analysis was performed using Hemavet (Drew
Scientific). Manual blood counts were conducted with a hemacytometer
(Fisher Scientific) using trypan blue staining (Sigma-Aldrich). Cytospins from
blood, placenta, and fetal liver were generated using a Shandon Cytospin 4
(Thermo Electron). Air-dried slides were stained with MGG stain (Sigma-
Aldrich). Images were taken using an Olympus BX51 microscope with a
DP72 camera. Pregnant mice were injected intraperitoneally with BrdU 1 hr
before harvesting embryos (FITC BrdU Flow Kit; BD PharMingen). Tissues
were processed for FACS or fixed frozen in O.C.T. for immunostaining. See
Supplemental Experimental Procedures for details.
Verification of Direct Regulation of Epo Expression in Trophoblasts
by PDGF-B Signaling
IF was used to localize Epo, PDGFRb, and PDGF-B in the placenta. PDGF-B
signaling-mediated regulation of EPO in trophoblasts was assessed by lenti-
viral shRNA knockdown of PDGFRb (Open Biosystems; clone B11) in human
BeWo trophoblast cell line. Secreted EPO was measured 48 hr after PDGF-B
(10 ng/ml) (PeproTech) stimulation at 8%oxygen using hEpo ELISAQuantikine
Kit (R&D Systems). See Supplemental Experimental Procedures for details.
Documentation of Ectopic Erythropoiesis in the Placenta upon
Trophoblast-Specific EPO Overexpression
The effect of hEPO overexpression in placental trophoblasts in vivo was
assessed using trophoblast-specific lentiviral gene manipulation. Lentiviral
vector particles overexpressing hEPO from the ubiquitin promoter were
injected under the zona pellucida of blastocysts, which were transferred to
pseudo-pregnant females. Ectopic erythropoiesis in transduced placentas
(EPO OE) was assessed using IF, IHC, and FACS. See Supplemental Experi-
mental Procedures for details.
Graphical and Statistical Analysis
Mathematical analysis and statistics were performed using GraphPad Prism
Software. Unpaired Student’s t tests were used to calculate p values, and
data are reported as mean ± SEM.658 Developmental Cell 22, 651–659, March 13, 2012 ª2012 ElsevierSUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.devcel.2011.12.022.
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